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Background: This case report highlights the relevance of quantifying the BCR-ABL gene in cerebrospinal fluid of
patients with suspected relapse of chronic myeloid leukemia in the central nervous system.
Case presentation: We report on a female patient with isolated central nervous system relapse of chronic myeloid
leukemia (CML) during peripheral remission after allogeneic hematopoietic stem cell transplantation. The patient
showed a progressive cognitive decline as the main symptom. MRI revealed a hydrocephalus and an increase in
cell count in the cerebrospinal fluid (CSF) with around 50% immature blasts in the differential count. A highly
elevated BCR-ABL/ ABL ratio was detected in the CSF, whilst the ratio for peripheral blood and bone marrow was
not altered. On treatment of the malresorptive hydrocephalus with shunt surgery, the patient showed an initial
cognitive improvement, followed by a secondary deterioration. At this time, the cranial MRI showed leukemic
infiltration of lateral ventricles walls. Hence, intrathecal administration of cytarabine, methotrexate, and
dexamethasone was initiated, which caused a significant decrease of cells in the CSF. Soon after, the patient
demonstrated significant cognitive improvement with a good participation in daily activities. At a later time point,
after the patient had lost the major molecular response of CML, therapy with dasatinib was initiated. In a further
follow-up, the patient was neurologically and hematologically stable.
Conclusions: In patients with treated CML, the rare case of an isolated CNS blast crisis has to be taken into account
if neurological symptoms evolve. The analysis of BCR-ABL in the CSF is a further option for the reliable detection of
primary isolated relapse of CML in these patients.
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Chronic myeloid leukemia (CML) is a myeloproliferative
disorder characterized by the presence of the Philadel-
phia chromosome which is caused by a reciprocal trans-
location between chromosome 9 and 22. The result is a
fusion gene from a part of the BCR (breakpoint cluster
region) gene from chromosome 22 and the Abl1 gene
from chromosome 9 [1]. Further, extramedullary blast
crisis is a known complication of CML. However, the* Correspondence: Hubertus.Axer@med.uni-jena.de
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reproduction in any medium, provided the orcentral nervous system as an isolated site of extramedul-
lary blast crisis is rare [2].
We report on a 64 year-old woman with CML in re-
mission who developed an isolated central nervous sys-
tem relapse after an unrelated one antigen mismatched
allogeneic hematopoietic stem cell transplantation.Case presentation
CML was first diagnosed in January 2005 with a blast cri-
sis. The patient was subsequently treated with imatinib. In
November 2005, therapy was changed to cytosine arabino-
side and mitoxantrone followed by hydroyurea due to a
second blast crisis. Since February 2006, the second gener-
ation tyrosine-kinase inhibitor (TKI) dasatinib induced atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antigen mismatched (C-allele locus) unrelated allogeneic
hematopoietic stem cell transplantation (SCT) was per-
formed in May 2006. After SCT, she developed a series of
epileptic seizures owing to posterior reversible encephal-
opathy syndrome (PRES) and developed severe critical ill-
ness polyneuropathy. At this time point, the analysis of
the CSF was normal (1 cell/μl, total protein 355 mg/l)
pointing neither to inflammation nor to a relapse. After
initial severe tetraplegia, she reconstituted during inten-
sive rehabilitation therapy and could use her arms inde-
pendently, but did not regain her ability to walk. Up to
November 2007, the patient received immunosuppressive
therapy with ciclosporine and low dose prednisolone was
administered until May 2008 because of a mild hepatic
graft-versus-host disease. Cognition remained unimpaired.
In all follow-up hematological visits after transplant, CML
was regarded to be in remission (major cytogenetic and
major molecular).
In November 2008, a progressive cognitive decline
within a period of 6 months was noticed which led to a
neurological consultation. The patient was mutistic and
apathetic showing psychomotorical impairment and
pathologically inadequate laughter. Moreover, orientation
regarding time and place was impaired, but spastic tetra-
plegia was unchanged. MRI revealed a hydrocephalus
with signs of high brain pressure (Figure 1 A-C). A lumbar
puncture showed an elevated total cell count (389 cells /μl)
and total protein (1154 mg/l) with an increased pressure
of 26.5 cm H2O. Thus, 30 ml of CSF was drained leading
to a significant cognitive improvement.
CSF microbiology excluded an infectious cause of the
pleocytosis. In the differential count of CSF, about 50%
immature blasts were counted and 65% myeloid precur-
sor cells (CD7/CD33 double positive) were detected by
FACS-analysis. However, the peripheral blood differen-
tial count was normal and did not point to a systemic
hematological relapse of CML. The BCR-ABL/ ABL
ratio (real time PCR) in CSF was 61.44% (and 0.0025%
in the bone marrow).
The malresorptive hydrocephalus was at first treated
with shunt surgery since the hydrocephalus was thought
to be the major pathophysiologic factor causing cogni-
tive decline in the patient. Following surgery, the CSF
cell count fell to 66 cells/μl. However, after initial cogni-
tive improvement, the patient showed a secondary de-
terioration. At this time point, leukemic infiltration in
the lateral ventricles walls was detected by cranial MRI
(Figure 1 D-F). Total cell and total protein counts were
1024 cells/μl and 2923 mg/l, respectively, and 66% of the
cells were CD7/CD33 double positive by FACS-analysis.
In the CSF, differential count megakaryocytes, immature
eosinophils and blast cells were noted. (Figure 1 G). The
BCR-ABL/ABL ratio (real time PCR) in the bone marrowhad increased from 0.0025% in the previous analysis to
0.07%.
Triple intrathecal therapy consisting of cytarabine
(40 mg), methotrexate (10 mg), and dexamethasone
(4 mg) was initiated, as described in the literature for
cases of CNS relapse [2-4]. Intrathecal chemotherapy
was administered twice and caused a significant decrease
of total cell count and protein in the CSF (11 cells/μl,
1254 mg/l protein). Myeloid precursor cells were reduced
to 19% by FACS-analysis. During follow-up examinations,
cognition of the patient was much improved and she
showed good participation in daily activities.
Therapy with dasatinib was begun after initial intra-
thecal chemotherapy, due to its ability to cross the
blood–brain barrier [5] and because the major molecular
response was lost in the consecutive bone marrow aspir-
ation in February 2009 (BCR-ABL/ ABL ratio (real time
PCR): 0.24%). Since then, the patient has remained
neurologically stable with subjective improvement of her
impaired daily activities. No hematological relapse oc-
curred during further patient follow up and continuous
dasatinib therapy. However, the patient was diagnosed
with advanced vulva carcinoma in May 2011 and died in
December of the same year.
Discussion
BCR-ABL transcripts are regarded as early markers for a
hematological relapse of CML [1]. Oral tyrosine kinase
inhibitors such as imatinib inhibit BCR-ABL-tyrosine kin-
ase. However, imatinib does not penetrate the blood–brain-
barrier so that isolated CNS blast crises have been
described in several cases [2-4]. Single cases of isolated
CNS blast crises have also been depicted, for example, in
one patient under dasatinib [6], a second generation TKI
with an improved penetration of the blood–brain-barrier,
and after allogeneic hematopoietic stem cell transplant-
ation in two cases [7]. Thus, the CNS has to be regarded
as a sanctuary site of relapse. This may generally be
caused by decreased levels of the drugs being found in
the CNS [2]. The history of CNS involvement before
hematopoietic stem cell transplantation has been identi-
fied as significant predictors for CNS relapse after
hematopoietic stem cell transplantation [7].
The isolated CNS relapse in our patient was detected
due to the presence of blasts and other myeloid precur-
sor cells in the CSF as well as increased BCR-ABL quan-
tities over time, while blood and bone marrow did not
reveal such abnormalities at that time. The increase of
cells in CNS led to a malresorptive hydrocephalus which
had to be treated with shunt surgery. The treatment of
isolated CNS relapse comprises of intrathecal chemo-
therapy and/or cranial irradiation [7]. Donor lymphocyte
infusion (DLI) was not considered as the first thera-
peutic option in this case, due to the dramatical clinical
Figure 1 MR and CSF: First MR showed a hydrocephalic enlargement of the lateral ventricles (A FLAIR, B Gd-enhanced T1w, C T2w),
while gadolinium-enhanced T1w did not show significant enhancement (B). Follow-up MR after secondary deterioration of the patient:
showed leukemic infiltrations of the lateral ventricles walls (D FLAIR, E and F Gd enhanced T1w). CSF (G) revealed immature blasts with a
pathological plasma-nucleus relation and basophilia of cytoplasm.
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duction of CSF cells indicating successful control of
CNS disease besides the neurological improvement, so
that additional radiotherapy was not considered.Conclusion
In patients with treated CML, the rare case of an iso-
lated CNS blast crisis has to be taken into account if
neurological symptoms evolve. Lumbar puncture is ob-
ligatory and isolated CNS relapse of leukaemia can be
controlled. The analysis of BCR-ABL in the CSF is a fur-
ther option either for reliable detection of isolated re-
lapse or as the first sign of a consecutive hematological
relapse of CML.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for re-
view by the Editor in Chief of this journal.Abbreviations
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